TY - JOUR AN - 33 AU - Hurwitz,H. AU - Fehrenbacher,L. AU - Cartwright,T. TI - Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluoruracil, leucovorin) as first line therapy in subjects with metastatic CRC. JO - Proc Am Soc Clin Oncol PY - 2003 VL - 22 SP - 3636- M2 - 3636 ER -